Dr Zacharoff offered several tips to PAINWeek attendees to help improve their communication with patients.
Dr Prasad highlights the importance of interdisciplinary approaches to the management of chronic pain.
Perioperative and emergency department use of non-steroidal anti-inflammatory drugs as part of a multimodal analgesia regimen may improve pain control in pediatric populations and avoid opioid-related adverse events.
DFN-11, a 3 mg subcutaneous (SC) sumatriptan autoinjector, may provide an alternative to SC sumatriptan 6 mg for individuals with episodic migraine, as it was found to have a lower incidence of side effects and injection site reactions.
A clinical pathway designed to reduce variations in opioid prescriptions for acute pain in children discharged after orthopedic surgery, was found to be effective in reducing prescriptions while maintaining analgesia.
Dr Harden provides an overview of the use of ketamine as an analgesic and its associated side effects.
Clinicians are reducing or discontinuing opioid therapy for patients in light of the 2016 guidelines for opioid prescribing by primary care physicians issued by the CDC.
Nucynta extended-release (ER) may be associated with lower rates of abuse compared with other ER opioid medications.
Lasmiditan was found to be more effective compared with placebo in eliminating pain and other symptoms associated with headache in individuals with migraine.
A topical lidocaine delivery system (ZTlido™) may be safe, effective, and well tolerated, and be bioequivalent to a lidocaine patch (Lidoderm®, 5%, 700 mg), with superior adhesion properties.
Clinicians should get their patients tested for drugs before prescribing them opioid or benzodiazepine medications—and on a regular basis when patients are on those drugs—as drug-drug interactions may be associated with risks.
Investigator analyzed the number of scripts and days of therapy in patients with migraine to determine use and frequency of overuse.
Naldemedine is a peripherally acting μ-opioid receptor antagonist approved for opioid-induced constipation in adults with chronic non-cancer related pain.
Fremanezumab may be efficacious for the prophylaxis of chronic migraine in individuals with comorbid migraine and moderate/moderate to severe depression.
Dr Argoff presented an overview of diagnostic tests and available treatments for small-fiber polyneuropathies.
A single dose of ibuprofen was superior to acetaminophen plus codeine for reducing pain 6 hours after a third molar extraction.
Oxycodone ARIR (RoxyBondTM), a novel abuse-deterrent formulation of immediate-release oxycodone, may have comparable safety and efficacy to IR oxycodone.
In patients with osteoarthritis, chronic pain is a primary symptom that may limit daily activities and impair function.
Lofexidine May Effectively Alleviate Withdrawal Symptoms After Discontinuation From Short-Acting OpioidsSeptember 06, 2018
Lofexidine may effectively alleviate opioid withdrawal symptoms.
Few patients were found to take triptan medications to treat acute migraine, and a majority of those who had, discontinued the treatment due to side effects.
For patients with irritable bowel syndrome with diarrhea who had an inadequate response to loperamide, eluxadoline may effectively reduce abdominal pain over a 12-week period.
Despite its low rate of abuse, tapentadol may still represent a public health burden.
Fremanezumab treatment may be efficacious in reducing the number of monthly headache days in the long-term in people with chronic migraine.
Dr Darnall presented an overview of the role played by psychology and behavioral interventions in the management of chronic pain.
Dr Mackey discussed potential applications of machine learning technology in chronic pain management and research.
Dr Cosio presented results from a preliminary study examining the prevalence of mental health disorders in veterans with chronic pain.
Dr Glick gave an overview of direct and indirect generators of neck pain and exposed some of the deficiencies of regional examinations for the differential diagnosis of this condition.
Investigators presented the results from a preliminary study examining the effect of an acceptance and commitment therapy in individuals with chronic pain.
Clinical Pain Advisor will be providing live coverage of the 12th annual PAINWeek conference, held September 4-8, 2018, in Las Vegas, Nevada.
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Patterns of Non-Medical Prescription Opioid Use in Adolescents
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds